Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Dermatol Ther ; 35(3): e15279, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1583588

ABSTRACT

Leukocytoclastic vasculitis (LCV) is the vasculitis of small vessels. In this report, we describe a 38-year-old male patient who presented to our outpatient clinic with a 1-week history of rash on his lower extremities that had started 4 days after receiving the Pfizer-BioNTech SARS-CoV-2 vaccine. A diagnosis of LCV was made based on clinical and histopathological findings. The patient was treated with antihistamines and prednisolone, after which improvement was observed in the lesions. With this paper, we aim to raise awareness concerning the possibility of LCV development after COVID-19 vaccination.


Subject(s)
BNT162 Vaccine/adverse effects , COVID-19 , Vaccination , Vasculitis, Leukocytoclastic, Cutaneous , Adult , COVID-19/prevention & control , Histamine Antagonists/therapeutic use , Humans , Male , Prednisolone/therapeutic use , SARS-CoV-2 , Vaccination/adverse effects , Vasculitis, Leukocytoclastic, Cutaneous/chemically induced , Vasculitis, Leukocytoclastic, Cutaneous/diagnosis , Vasculitis, Leukocytoclastic, Cutaneous/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL